Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

Curr Atheroscler Rep. 2019 Jul 27;21(10):41. doi: 10.1007/s11883-019-0800-z.

Abstract

Purpose of review: We summarize the best evidence for statins in the prevention and treatment of heart failure.

Recent findings: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart failure-mainly by preventing myocardial infarction although an additional benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are proportionately much less common in these patients than heart failure hospitalization or death). Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy and in which polypharmacy is a problem.

Keywords: Coronary disease; Heart failure; Prevention; Statin.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Cholesterol, LDL / blood
  • Coronary Artery Disease / drug therapy
  • Heart Failure / drug therapy*
  • Heart Failure / prevention & control*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Middle Aged
  • Myocardial Infarction / prevention & control
  • Polypharmacy
  • Young Adult

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors